Zacks Small Cap Increases Earnings Estimates for VolitionRx

VolitionRx Limited (NYSE:VNRX) – Analysts at Zacks Small Cap raised their FY2024 EPS estimates for shares of VolitionRx in a research note issued to investors on Wednesday, December 4th. Zacks Small Cap analyst S. Ralston now expects that the company will earn ($0.28) per share for the year, up from their previous forecast of ($0.29). The consensus estimate for VolitionRx’s current full-year earnings is ($0.31) per share. Zacks Small Cap also issued estimates for VolitionRx’s Q4 2024 earnings at ($0.06) EPS.

VNRX has been the topic of a number of other reports. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com began coverage on shares of VolitionRx in a report on Friday. They set a “sell” rating on the stock.

VolitionRx Stock Performance

VolitionRx stock opened at $0.59 on Monday. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23. The firm has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $0.67. The firm has a market cap of $54.68 million, a price-to-earnings ratio of -1.64 and a beta of 1.17.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC increased its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the quarter. Geode Capital Management LLC owned 0.79% of VolitionRx worth $439,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.